Dear colleagues,
We send you the two significant documents regarding the new prescription methods introduced with the decree concerning the ossiap spending review.
1) law published in the official gazette.
2) explanatory note published on the AIFA website
We suggest everyone to print them for the interview with the doctors in case there are doubts or simplistic positions that have emerged in these days on several levels
IMPORTANT POINTS to highlight:
THE LAW IS NOT ABOUT
1) drugs covered by patent
2) class C
3) white recipe
In all these cases the Brand can be prescribed without any problem
Drug prescription GENERATED on prescription SNN:
1) CONTINUING CHRONIC THERAPY the BRAND can continue to be prescribed without any problems
—————–
2) FIRST treatment NEW CHRONIC patient o
3) FIRST treatment of NEW NON-chronic episode
In these two cases the doctor has 3 CHOICES:
1) ACTIVE PRINCIPLE +BRAND
2) ACTIVE INGREDIENT + BRAND + NOT REPLACEABLE + SYNTHETIC MOTIVATION
